Caveolin 3

A caveolin that is expressed exclusively in MUSCLE CELLS and is sufficient to form CAVEOLAE in SARCOLEMMA. Mutations in caveolin 3 are associated with multiple muscle diseases including DISTAL MYOPATHY and LIMB-GIRDLE MUSCULAR DYSTROPHY.

Also Known As:

Networked: 234 relevant articles (9 outcomes, 14 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Lisanti, Michael P: 12 articles (01/2015 - 01/2002)
2.	Patel, Hemal H: 9 articles (01/2020 - 01/2008)
3.	Roth, David M: 9 articles (01/2020 - 01/2008)
4.	Sunada, Yoshihide: 7 articles (01/2013 - 01/2004)
5.	Minetti, C: 7 articles (01/2011 - 03/2000)
6.	Lisanti, M P: 7 articles (02/2004 - 03/2000)
7.	Ackerman, Michael J: 6 articles (11/2020 - 11/2006)
8.	Balijepalli, Ravi C: 6 articles (01/2019 - 11/2006)
9.	Ishikawa, Yoshihiro: 6 articles (09/2014 - 12/2002)
10.	Tsutsumi, Yasuo M: 5 articles (09/2014 - 01/2008)

Related Diseases

1.	Reperfusion Injury 12/10/2021 - "Correction: Inhibition of PKCβ2 overexpression ameliorates myocardial ischaemia/reperfusion injury in diabetic rats via restoring caveolin-3/Akt signaling." 08/01/2015 - "Inhibition of PKCβ2 overexpression ameliorates myocardial ischaemia/reperfusion injury in diabetic rats via restoring caveolin-3/Akt signaling." 09/07/2014 - "We conclude that caveolae and caveolin-3 are critical for exendin-4 induced protection of the heart from ischemia/reperfusion injury." 01/01/2008 - "We conclude that caveolae and caveolin-3 are critical for volatile anesthetic-induced protection of the heart from ischemia/reperfusion injury." 04/01/2012 - "Compared with wild-type mice, caveolin-3 knockout (Cav-3KO) mice exhibited modestly increased myocardial ischemia/reperfusion injury (increased infarct size, apoptosis, and poorer cardiac function recovery; P<0.05). "
2.	Infarction (Infarctions) 01/01/2017 - "Enhanced cardiac function, reduced infarct size and preserved ultrastructure of cardiomyocytes were associated with increased formation of caveolar structures, augmented levels of caveolin-3 and mitochondrial ERK1/2 activation in PostC hearts in both subsarcolemmal (SSM) and interfibrillar (IFM) subpopulations. " 04/01/2012 - "Compared with wild-type mice, caveolin-3 knockout (Cav-3KO) mice exhibited modestly increased myocardial ischemia/reperfusion injury (increased infarct size, apoptosis, and poorer cardiac function recovery; P<0.05). " 04/01/2015 - "The combination of isoflurane and exendin-4 reduced infarct size, but it was not more effective than either agent alone, and the cardioprotective effects of these agents are mediated by caveolin-3 expression." 04/01/2015 - "Pharmacological preconditioning (isoflurane at 1.0 MAC, 30 ng/kg i.v. exendin-4, or isoflurane at 0.5 MAC with 3 ng/kg i.v. exendin-4) increased caveolin-3 protein expression in the heart after infarct induction. " 01/01/2008 - "Membrane fractionation by sucrose density gradient centrifugation of CM treated with MbetaCD or colchicine revealed that buoyant (caveolae-enriched) fractions had decreased phosphocaveolin-1 and caveolin-3 compared to control CM. Cardiac protection in vivo was assessed by measurement of infarct size relative to the area at risk and cardiac troponin levels. "
3.	Neoplasms (Cancer) 02/01/2009 - "Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation." 01/01/2002 - "Samples with high levels of caveolin-3 tended to have higher degrees of tumor-infiltrating immune cells, although this finding was not statistically significant. " 01/01/2002 - "Tumor-infiltrating immune cells were also studied immunohistochemically, and the correlation between the number of immune cells and caveolin-3 concentrations was calculated. " 01/01/2015 - "MURC/cavin-4 Is Co-Expressed with Caveolin-3 in Rhabdomyosarcoma Tumors and Its Silencing Prevents Myogenic Differentiation in the Human Embryonal RD Cell Line." 01/01/2015 - "The purpose of this study was to investigate whether MURC/cavin-4, a plasma membrane and Z-line associated protein exhibiting an overlapping distribution with Caveolin-3 (Cav-3) in heart and muscle tissues, may be expressed and play a role in rhabdomyosarcoma (RMS), an aggressive myogenic tumor affecting childhood. "
4.	Cardiomegaly (Heart Hypertrophy) 09/01/2001 - "A decrease in caveolin-3 expression may play a role in the development of cardiac hypertrophy in SHR, presumably through de-regulating the inhibition of growth signal in the hearts of SHR in the hypertrophic stage." 01/01/2016 - "PTRF/Cavin-1 deficiency shows reductions of caveolae and caveolin-3 (Cav3) protein expression in skeletal muscle, and Cav3 deficiency in the heart causes cardiac hypertrophy with loss of caveolae. " 09/04/2015 - "Caveolin-3 Overexpression Attenuates Cardiac Hypertrophy via Inhibition of T-type Ca2+ Current Modulated by Protein Kinase Cα in Cardiomyocytes." 05/31/2011 - "Cardiac-specific overexpression of caveolin-3 attenuates cardiac hypertrophy and increases natriuretic peptide expression and signaling." 04/30/2009 - "Our data suggest that the alterations in nuclear and mitochondrial activation of STAT3 and caveolae localization of caveolin-3 are related to the development of the catecholamine-induced cardiac hypertrophy."
5.	Hypoxia (Hypoxemia) 01/01/2016 - "Hypoxic postconditioning-induced protection against hypoxia/reoxygenation injury was lost in Adipo(-/-) cardiomyocytes but restored by recombinant APN, but this APN beneficial effect was abolished by specific STAT3 or APN receptor 1 (AdipoR1) gene knockdown, or caveolin-3 (Cav3) disruption. " 01/01/2018 - "FAT10 attenuates hypoxia-induced cardiomyocyte apoptosis by stabilizing caveolin-3." 10/15/2000 - "These data suggest that a decrease in caveolin-3 plays a role in the mechanisms by which chronic hypoxia increases NOS3 activity in the myocardium." 10/15/2000 - "Immunoblots of normoxic and hypoxic hearts showed that chronic hypoxia decreases the amount of caveolin-3 in heart homogenates by 2. 2 +/- 0.5-fold. " 11/01/2020 - "FAT10 may be cardioprotective in ischemia and hypoxia through attenuation of hypoxia-induced cardiomyocyte apoptosis regulated by the BCL2/BAX ratio and caveolin-3. "

Related Drugs and Biologics

1.	Caveolin 3
2.	Proteins (Proteins, Gene)
3.	Basigin (Extracellular Matrix Metalloproteinase Inducer (EMMPRIN))
4.	Profilins (Profilin)
5.	Isoflurane
6.	Exenatide (Byetta)
7.	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
8.	Matrix Metalloproteinases (MMPs)
9.	Phosphotransferases (Kinase)
10.	nitroxyl

Related Therapies and Procedures

1.	Ischemic Postconditioning
2.	Therapeutics
3.	Plasmapheresis
4.	Ovariectomy (Oophorectomy)
5.	Drug Therapy (Chemotherapy)